An observational study in Autoimmune Encephalitis and Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis, sponsored by Shen Chun-Hong. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by Shen Chun-Hong · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Autoimmune Diseases of the Nervous System with a site in China — 18 open to participants now, 20 under way, 3 of them phase 3. Autoimmune Diseases of the Nervous System · China.
Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2022, is one of 13 observational ones, reaches primary completion later than 11 of the 19 other live ones, and was the 8th registered.
123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.
Browse Autoimmune Diseases of the Nervous System studies →18 of the 26 studies in Autoimmune Diseases of the Nervous System with a site in China are open now. Recruiting first, the newest first:
Beijing Tongren Hospital · Sites in China
Ages 18+
Tongji Hospital · Sites in China
Ages 18–75
Tongji Hospital · Sites in China
Ages 18–70
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tongji Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 160 across 57 observational studies indexed under Autoimmune Diseases of the Nervous System.
Median enrollment 36 across the 13 interventional studies, 300 across the 13 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 26 have an industry lead sponsor. The 10 most frequent:
Shen Chun-Hong is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Shen Chun-Hong has 3 studies filed under Autoimmune Diseases of the Nervous System — fewer than ten, so there is no comparison to draw.
6 of the studies in Autoimmune Diseases of the Nervous System with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05503264Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | 2026-12-16 |
| NCT07337785Tongji HospitalCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | 2026-12-01 |
| NCT06388161Shen Chun-HongNeural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology | 2026-12-31 |
| NCT06797024Tongji HospitalJY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders | 2026-12-31 |
| NCT04561557Tongji HospitalSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | 2027-02-22 |
Add all 6 to your calendar (.ics) → With an account.
Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases.
So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.
In this prospective study, the investigators are aiming to recruit newly diagnosed patients with anti-LGI1 encephalitis. At the acute stage and during the follow-up, some routine and advanced paraclinical examinations will be conducted, including dynamic blood and/or cerebrospinal fluid (CSF) test, multimodal brain magnetic resonance imaging (MRI) including functional MRI, diffusion tensor imaging, arterial spin labeling, et al), Electroencephalography (EEG) or continuous video-EEG (VEEG), positron emission tomography (PET), neuropsychological tests and some other paraclinical examinations. Through the comprehensive analysis, the clinical outcomes and associated factors are further explored in anti-LGI1 encephalitis.
the patients with anti-LGI1 encephalitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
seizure outcomes
The incidence of different seizure outcomes and associated factors will be analyzed.
Time frame: 1 year, 2 year
Clinical severity and recovery 1
modified Rankin scale, ranging from 0-6, higher scores mean a worse outcome
Time frame: 1 year, 2 year
Clinical severity and recovery 2
clinical assessment scale for autoimmune encephalitis, ranging from 0-27, higher scores mean a worse outcome
Time frame: 1 year, 2 year
Incidence of recurrence
a relapse of encephalitis
Time frame: 1 year, 2 year
Memory assessment 1
the Wechsler Memory Scale, high score means a good memory.
Time frame: 1 year, 2 year
Memory assessment 2
Rey Auditory Verbal Learning Test (RAVLT), high score means a good vebal episodic memory.
Time frame: 1 year, 2 year
Brain volume
with 3T magnetic resonance imaging (MRI), volumes of the whole hippocampus, hippocampal subfields and other relevant regions were determined using FreeSurfer. The unit of volume is described as mm3.
Time frame: 1 year, 2 year
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.
Of 28 observational studies under Autoimmune Diseases of the Nervous System, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 17. This study's planned 67 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Autoimmune Diseases of the Nervous System →